Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Metastatic Breast Cancer
Sponsor: University Hospital Tuebingen